Loading…
Ascendis Pharma A/S is projected to rise to $321.29 by 2027, a +37% move from its current price of $235.26. ASND is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $230.80 | $235.33 | $239.94 | +0.03% |
| May 30 | $229.02 | $235.39 | $241.95 | +0.06% |
| May 31 | $227.67 | $235.46 | $243.51 | +0.08% |
| Jun 1 | $226.55 | $235.52 | $244.85 | +0.11% |
| Jun 2 | $225.58 | $235.59 | $246.04 | +0.14% |
| Jun 3 | $224.71 | $235.66 | $247.14 | +0.17% |
| Jun 4 | $223.92 | $235.72 | $248.15 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $223.92 | $235.72 | $248.15 | +0.20% |
| Week 2 | $219.64 | $236.19 | $253.98 | +0.39% |
| Week 3 | $216.51 | $236.65 | $258.67 | +0.59% |
| Week 4 | $213.97 | $237.12 | $262.77 | +0.79% |
| Week 5 | $211.80 | $237.58 | $266.50 | +0.99% |
| Week 6 | $209.91 | $238.05 | $269.97 | +1.19% |
| Week 7 | $208.21 | $238.52 | $273.24 | +1.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ascendis Pharma A/S is a biopharmaceutical company that develops TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The description places the company in the healthcare sector and highlights its focus on endocrinology and oncology programs. It operates SKYTROFA for treating pediatric patients with growth hormone deficiency and YORVIPATH, a once-daily subcutaneous injection for adults with chronic hypoparathyroidism.
Ascendis Pharma was incorporated in 2006 and is based in Hellerup, Denmark.
ASND is Ascendis Pharma A/S, a healthcare company in the biopharmaceutical space. The stock is currently priced at $247.05 and has a market capitalization of $15.26B, with a rank of 692. The long-run price outlook is positive, with forecast averages rising to $548.92 by 2030, $1,464.92 by 2040, and $3,243.16 by 2050.
In the nearer term, the forecast sequence begins with 2026 showing an avg of $247.05 and a min of $202.99 to a max of $349.31, indicating an upward trajectory across the coming years.
A major floor 12.5% below — a decisive break under it would weaken the trend.
The nearest floor, 6.4% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 11.2% above — clearing it would confirm fresh momentum.
Key ASND support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ASND market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $242.16 | Sell | $240.12 | Sell |
| MA 10 | $241.60 | Sell | $240.18 | Sell |
| MA 20 | $236.88 | Sell | $238.43 | Sell |
| MA 50 | $232.88 | Buy | $234.36 | Buy |
| MA 100 | $228.78 | Buy | $227.94 | Buy |
| MA 200 | $215.77 | Buy | $214.35 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.21 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -17.30 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -1.42 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.15 | Buy |
| Awesome (5,34) | 4.93 | Buy |
| Ultimate (7,14,28) | 43.43 | Neutral |
| Momentum (10) | -2.39 | Sell |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 242.45 | Sell |
| ADX (14) | 10.97 | Neutral |
| ATR (14) | 4.45 | Info |
The near-term technical picture is bullish, supported by a bullish sentiment in the current setup. RSI(14) is 60, and the stock trades with a 50-day simple moving average of $232.52 and a 200-day simple moving average of $215.30. Key technical levels place support at $220.28 and resistance at $249.84, with a 30-day trading range from $217.81 up to $280.22.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $202.99 | $235.26 | $327.18 | 0% | Neutral | |
| $261.95 | $321.29 | $412.85 | +37% | Bullish | |
| $308.41 | $385.41 | $508.54 | +64% | Bullish | |
| $355.10 | $450.69 | $607.38 | +92% | Bullish | |
| $386.17 | $496.88 | $681.79 | +111% | Bullish | |
| $416.37 | $542.43 | $756.18 | +131% | Bullish | |
| $436.35 | $575.04 | $813.20 | +144% | Bullish | |
| $482.65 | $642.95 | $921.18 | +173% | Bullish | |
| $587.75 | $790.97 | $1,147.00 | +236% | Bullish | |
| $652.20 | $886.26 | $1,299.72 | +277% | Bullish | |
| $882.79 | $1,252.89 | $1,927.02 | +433% | Bullish | |
| $1,786.69 | $2,726.52 | $4,500.78 | +10.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $202.99 | $235.26 | $276.44 | +0.00% |
| June 2026 | $208.05 | $242.81 | $288.96 | +3.21% |
| July 2026 | $205.59 | $241.36 | $290.04 | -0.60% |
| August 2026 | $205.01 | $241.81 | $292.75 | +0.18% |
| September 2026 | $212.15 | $251.18 | $305.96 | +3.88% |
| October 2026 | $216.94 | $257.76 | $315.71 | +2.62% |
| November 2026 | $216.49 | $258.02 | $317.56 | +0.10% |
| December 2026 | $221.38 | $264.62 | $327.18 | +2.56% |
Click any year to see its month-by-month ASND forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Ascendis Pharma A/S's 2026 outlook centres on $235.26, within a $202.99 to $327.18 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, ASND could reach as high as $412.85, with a base case around $321.29 and support toward $261.95 — roughly +37% from $235.26. Momentum favours further upside here.
Expect ASND to range from $308.41 to $508.54 through 2028. The $385.41 average target implies a +64% move from current prices. That is up +20% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The ASND price prediction for 2029 points to an average of $450.69 (low $355.10, high $607.38) — a potential gain of +92% on today's $235.26. Momentum favours further upside here.
In 2030, ASND is projected to trade between $386.17 and $681.79, averaging $496.88 — a potential gain of +111% from today's $235.26. That is up +10% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Ascendis Pharma A/S's 2031 outlook centres on $542.43, within a $416.37 to $756.18 range. That is up +9% on the projected 2030 average. That marks a +131% change versus current levels. Momentum favours further upside here.
By 2032, ASND could reach as high as $813.20, with a base case around $575.04 and support toward $436.35 — roughly +144% from $235.26. Buyers look set to stay in control over this stretch.
Expect ASND to range from $482.65 to $921.18 through 2033. The $642.95 average target implies a +173% move from current prices. That is up +12% on the projected 2032 average. Momentum favours further upside here.
The ASND price prediction for 2034 points to an average of $790.97 (low $587.75, high $1,147.00) — a potential gain of +236% on today's $235.26. Buyers look set to stay in control over this stretch.
In 2035, ASND is projected to trade between $652.20 and $1,299.72, averaging $886.26 — a potential gain of +277% from today's $235.26. That is up +12% on the projected 2034 average. Momentum favours further upside here.
Ascendis Pharma A/S's 2040 outlook centres on $1,252.89, within a $882.79 to $1,927.02 range. That is up +41% on the projected 2035 average. That marks a +433% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, ASND could reach as high as $4,500.78, with a base case around $2,726.52 and support toward $1,786.69 — roughly +10.6x from $235.26. Momentum favours further upside here.
Investing $1,000 in ASND today (≈ 4.250616 ASND) could be worth
$11,589.39
+$10,589.39 (+1059%) by 2050 · US Dollar
Based on the average projected ASND price of $2,726.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ASNDwould be worth at today's price.
$1,000 invested in ASND on May 27, 2025 (≈ 6.358492 ASND) would be worth
$1,495.9
+$495.9 (+49.6%) today · 1.50× · US Dollar
Based on a ASND entry price of $157.27 vs. today's $235.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $241.34 | $974.81 | -2.5% |
| 1 month ago | $226.66 | $1,037.94 | +3.8% |
| 3 months ago | $228.99 | $1,027.38 | +2.7% |
| 6 months ago | $212.33 | $1,107.99 | +10.8% |
| 1 year ago | $157.27 | $1,495.9 | +49.6% |
| All time (5.0y) ago | $133.53 | $1,761.85 | +76.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ASND forecast.
Our base-case forecast reaches $470.00 around 2030.
Implied market cap at $470.00: $29.04B
The multi-year forecast shows a bullish trajectory across years, with rising average prices and substantial upside. By 2030, the forecasted average price is $548.92, with a minimum of $427.34 and a maximum of $751.55, and an ROI of 122.2% in a bullish context. By 2040, the average is forecast at $1,464.92, with a minimum of $1,035.86 and a maximum of $2,244.71, and an ROI of 493% in a bullish context.
By 2050, the average is forecast at $3,243.16, with a minimum of $2,135.96 and a maximum of $5,329.12, and an ROI of 1212.8% in a bullish context. These are estimates, not guarantees, and the long horizon reflects a wide range of potential outcomes as market conditions and development pathways evolve. The description notes a pipeline of three endocrinology rare disease candidates in clinical development and a focus on oncology therapeutics, which may influence long-term outcomes.
Tap a question to reveal the answer.
By 2030 the forecasted average price is $548.92, with a min of $427.34 and a max of $751.55; the ROI is 122.2% and sentiment is BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising average prices and meaningful upside, including an average of $346.86 in 2027 and an eventual average of $3,243.16 by 2050; the near term in 2026 is neutral with an average of $247.05 and ROI of 0%.
Yes. The long-term forecast shows the 2040 average price at $1,464.92 and the 2050 average at $3,243.16, both above $1,000, with bullish sentiment across the later years.
The current price is $247.05 and the market cap is $15.26B.
RSI(14) is 60 with a bullish sentiment. The 50-day SMA is $232.52 and the 200-day SMA is $215.30. Support is at $220.28 and resistance at $249.84, with a 30-day range of $217.81 to $280.22.
Ascendis Pharma A/S Community Discussion
0Share your Ascendis Pharma A/S price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.